PAVmed reports Q4 adjusted EPS (6c) vs. ($1.33) last year

Reports Q4 revenue $10,000 vs. $1.05M last year. “Following the critical steps taken to stabilize PAVmed’s (PAVM) corporate structure and balance sheet, PAVmed is now in a very strong position to operate as it was designed-as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “With Lucid and Veris both having sufficient capital to advance their commercial strategies, we expect PAVmed to directly benefit from their success. The performance of PAVmed’s subsidiaries, particularly Lucid and its recent achievements with EsoGuard, serve as key drivers of PAVmed’s long-term success and sustainability.”